Form 8-K Conatus Pharmaceuticals For: Dec 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright
December 6, 2018 9:16 AM ESTH.C. Wainwright analyst Ed Arce lowered the price target on Conatus Pharmaceuticals (NASDAQ: CNAT) to $14.00 (from $15.00) while maintaining a Buy rating.
Arce commented, "We fully expect CNAT shares to drop over 10% today as some investors will undoubtedly look no further at yesterday's release of the ENCORE-PH top-line results, than to see that the study missed its primary endpoint. Following this expected initial... More



